Approximately 15% of individuals with ovarian cancer and 40% with family history of ovarian cancer have pathogenic BRCA1 or BRCA2 germline mutations (gBRCA1/2) [1–3]. This evidence concerns the gene BRCA1 and ovarian carcinoma.